搜索
ss
ss
关于普米斯
About Us
t16

PM1268

Dupilumab (anti-IL-4Rα) has been approved for atopic dermatitis with good patient outcomes. However, the effect on inhibiting pruritus is moderate, and more than 50% of patients require improved treatment options. Nemolizumab, which blocks the IL-31/IL-31RA pathway, inhibits pruritus through a direct pathway on sensory nerves, which results in a rapid and robust onset of activity in patients with a reduction of itching and improvement of sleep quality. PM1268 is a bispecific antibody with Fc-silencing and half-life extension, which targets IL-4Rα and IL-31 simultaneously. This design provides a faster onset of efficacy and a potentially larger effect through the concomitant modulation of both pathways. 
t16
Product description
Parameters

Dupilumab (anti-IL-4Rα) has been approved for atopic dermatitis with good patient outcomes. However, the effect on inhibiting pruritus is moderate, and more than 50% of patients require improved treatment options. Nemolizumab, which blocks the IL-31/IL-31RA pathway, inhibits pruritus through a direct pathway on sensory nerves, which results in a rapid and robust onset of activity in patients with a reduction of itching and improvement of sleep quality. PM1268 is a bispecific antibody with Fc-silencing and half-life extension, which targets IL-4Rα and IL-31 simultaneously. This design provides a faster onset of efficacy and a potentially larger effect through the concomitant modulation of both pathways. 

Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table
Previous
Next
There is currently no content to display
Please add data record on website background.
There is currently no content to display
Please add data record on website background.

Copyright © 2022 Biotheus Inc. All Rights Reserved  粤ICP备2021122492号